AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02830295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
Study NCT03838692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: A daily oral dose at 30 mg.
Study NCT01245296 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Timing of clamping the umbilical cord
Description: The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
Study NCT01269502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temp Touch Diabetica Solutions inc.
Description: Daily measurement of skin temperature on feet for one year
Study NCT01269502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspection
Description: Inspection of feet daily for one year
Study NCT01338584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training 3 weeks before radical prostatectomy
Description: Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
Study NCT01338584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive preoperative pelvic floor muscle training
Description: Patient started to learn pelvic floor muscle 3 weeks before surgery
Study NCT04485884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose A
Description: One time dose of IN-C005 dose A taken orally.
Study NCT04485884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose B
Description: One time dose of IN-C005 dose B taken orally.
Study NCT04485884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose C
Description: One time dose of IN-C005 dose C taken orally.
Study NCT04485884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose D
Description: Oral administration of IN-C005 dose D once daily for 7 days.
Study NCT04485884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose E
Description: Oral administration of IN-C005 dose E once daily for 7 days.
Study NCT04485884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose F
Description: Oral administration of IN-C005 dose F once daily for 7 days.
Study NCT03807284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A group psychosocial course
Description: A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
Study NCT01731093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001
Study NCT01731093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04384523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 20 mg/kg IV
Description: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
Study NCT04384523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 40 mg/kg IV
Description: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
Study NCT04384523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 80 mg/kg IV
Description: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
Study NCT04384523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 140 mg/kg IV
Description: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
Study NCT04384523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 200 mg/kg IV
Description: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
Study NCT04384523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride)
Study NCT01227005 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of blood products
Description: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
Study NCT01683578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Variable Ventilation
Study NCT02554981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% Ophthalmic Emulsion
Description: Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
Study NCT02746185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
Study NCT02746185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
Study NCT04919837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low vision aids
Description: the assisting devices fitting for low-vision patients
Study NCT00934908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Green tea capsules taken twice a day.
Study NCT00934908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active sugar pill.
Study NCT04443166 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program
Description: a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
Study NCT04443166 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program
Description: a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
Study NCT03207802 — intervention group
Intervention type: DEVICE
Intervention: Discontinuation of using device
Description: Subject will be instructed to discontinuation of use of device
Study NCT01587235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Description: Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
Study NCT01587235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other Statin
Description: Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
Study NCT04785599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercices
Description: An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
Study NCT04785599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informative talk
Description: An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
Study NCT04785599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garment
Description: Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity.
Study NCT01961648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rebreathing bag
Study NCT01961648 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rebreathing
Study NCT01961648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask
Study NCT01961648 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mask
Study NCT03688568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib given orally as dose escalation treatment.
Study NCT04794881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 hours
Description: Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
Study NCT04794881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 48 hours
Description: Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
Study NCT00951028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)
Description: 12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
Study NCT02337907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: for blinding purposes
Study NCT01647477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interview
Description: 25 minutes of semi directive interview
Study NCT01647477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: questionnaires to answer at baseline 45 minutes
Study NCT02337907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: for blinding purposes
Study NCT02337907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for blinding purposes
Study NCT02337907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02337907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Study NCT02337907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Study NCT02838056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural injection
Description: drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
Study NCT02840045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-density electroencephalography
Description: Musical stimulation during electroencephalography recording
Study NCT03543332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measures of physical activity and kinesiophobia
Description: Groups will be compared regarding kinesiophobia with TSK heart.
Study NCT02930759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
Study NCT04170465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 mg Tablets
Description: Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
Study NCT04170465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC-T chemotherapy regimen
Description: AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
Study NCT04170465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-T chemotherapy regimen
Description: AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
Study NCT01774162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine needle biopsy using ProCore needle for histology.
Description: EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
Study NCT01774162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration using conventional FNA for cytology
Description: EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
Study NCT01647477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: questionnaires to answer at baseline 45 minutes
Study NCT01787123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cerebrolysin
Description: 14-day course of intravenous Cerebrolysin started within 4 days of ictus
Study NCT01787123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 14-day course of intravenous normal saline started within 4 days of ictus
Study NCT04121637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS.
Study NCT04121637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frenkel coordination exercises
Description: Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
Study NCT04121637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel coordination exercises
Description: Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
Study NCT01513824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pressure pain sensitivity measure followed bu acupressure
Description: twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
Study NCT02567240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon monoxide-bubbled mediums
Description: Islets will be harvested with carbon monoxide bubbled mediums
Study NCT01392235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: 25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT04269525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
Study NCT00805142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Description: Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
Study NCT04441151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation therapy
Description: Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
Study NCT02559180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
Study NCT00070551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV
Study NCT00070551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00867906 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cat-PAD
Description: Cat-PAD dose 1x8 administrations 2 weeks apart
Study NCT00867906 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo comparator, 1x8 administrations 2 weeks apart
Study NCT03331523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene/Betamethasone Dipropionate
Description: Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
Study NCT03331523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex®
Description: Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
Study NCT03331523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
Study NCT00070551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study NCT00070551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01140165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cheese
Description: the effect of cheese intake versus butter intake on blood lipids (primarily)
Study NCT01140165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheese
Description: the effect of cheese intake versus butter intake on blood lipids (primarily)
Study NCT03997773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-it Intervention
Description: The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
Study NCT02145715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Study NCT02145715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT02145715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00986362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: 175µg ocriplasmin intravitreal injection
Study NCT00986362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravitreal injection
Study NCT00812565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% isotonic sodium chloride solution.
Study NCT00812565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: octagam 10%
Description: octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
Study NCT03824093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFIX Only
Description: The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
Study NCT03824093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFIX+ Provider Communication Training
Description: The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
Study NCT00375518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
Study NCT00375518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
Study NCT02469519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone - ACTIVE
Description: antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
Study NCT02469519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline - PLACEBO
Description: normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
Study NCT00829959 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 1 - 2 questionnaires, lasting 10-15 minutes.